{
    "clinical_study": {
        "@rank": "99411", 
        "arm_group": {
            "arm_group_label": "Androgen suppression + EBRT + Brachytherapy", 
            "arm_group_type": "Experimental", 
            "description": "Androgen suppression with external beam radiation therapy followed by brachytherapy boost"
        }, 
        "brief_summary": {
            "textblock": "RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as\n      leuprolide, goserelin, flutamide, or bicalutamide, may stop the adrenal glands from making\n      androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving these\n      drugs together with radiation therapy may kill more tumor cells.\n\n      PURPOSE: This phase II trial is studying how well androgen suppression with either\n      leuprolide or goserelin and either flutamide or bicalutamide together with radiation therapy\n      works in treating patients with prostate cancer."
        }, 
        "brief_title": "Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer", 
        "completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the feasibility of androgen-suppression therapy combined with external-beam\n           radiotherapy and boost brachytherapy (EBRT+BT) in patients with intermediate-risk\n           localized prostate cancer.\n\n        -  Determine the safety of EBRT+BT in these patients.\n\n        -  Determine, in a preliminary manner, the efficacy of EBRT+BT in terms of rate of local\n           recurrence at 5 years, time to prostate-specific antigen failure, and time to first\n           rectal/bladder injury, in these patients.\n\n      OUTLINE: Patients receive either leuprolide intramuscularly or goserelin subcutaneously once\n      every 12 weeks for a total of 24 weeks. Patients also receive either oral flutamide three\n      times daily or oral bicalutamide once daily for 4 weeks.\n\n      Within 4 weeks after initiation of androgen-suppression therapy, patients undergo\n      external-beam radiotherapy (EBRT) once daily, 5 days a week, for 5 weeks. At 2-4 weeks after\n      completion of EBRT, patients undergo transrectal ultrasound-guided boost brachytherapy with\n      implanted iodine I 125 or palladium Pd 103 seeds.\n\n      Patients are followed every 3 months for 2 years and then every 6 months for 4 years.\n\n      PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed adenocarcinoma of the prostate\n\n               -  Must have one of the following prognostic factors:\n\n                    -  Stage T1-2, N0; prostate-specific antigen (PSA) \u2264 10 ng/mL; and Gleason\n                       score > 6\n\n                    -  Stage T1-2, N0; PSA > 10 ng/mL and < 20 ng/mL; and Gleason score \u2264 6\n\n                    -  Stage T3a, N0; PSA \u2264 10 ng/mL; and Gleason score \u2264 6\n\n          -  Prostate volume < 60 cc by transrectal ultrasound\n\n          -  No distant or nodal metastases\n\n               -  No metastatic disease by bone scan, CT scan, or MRI\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  ECOG 0-2\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Absolute neutrophil count \u2265 1,500/mm^3\n\n          -  Platelet count \u2265 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin \u2264 1.5 times upper limit of normal\n\n        Renal:\n\n          -  Not specified\n\n        Other:\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No prior immunotherapy for prostate cancer\n\n        Chemotherapy:\n\n          -  No prior chemotherapy for prostate cancer\n\n        Endocrine therapy:\n\n          -  Prior androgen-suppression therapy for up to 4 weeks duration allowed if initiated\n             within 4 weeks of study radiotherapy\n\n          -  No other prior hormonal therapy\n\n        Radiotherapy:\n\n          -  No prior radiotherapy for prostate cancer\n\n        Surgery:\n\n          -  No prior surgery for prostate cancer\n\n          -  No prior transurethral resection of the prostate\n\n        Other:\n\n          -  No prior alternative therapy (e.g., PC-SPES) for prostate cancer"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "63", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 4, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00006359", 
            "org_study_id": "CDR0000068228", 
            "secondary_id": [
                "U10CA031946", 
                "CALGB-99809"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Androgen suppression + EBRT + Brachytherapy", 
                "description": "Lupron: 22.5mg IM injection q 12 wks x 2 OR Zoladex:  10.8 mg subQ injection q 12 wks x 2", 
                "intervention_name": "LHRH agonist", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Androgen suppression + EBRT + Brachytherapy", 
                "description": "flutamide 250 mg PO tid for 4 wks OR casodex 50 mg PO daily for 4 wks", 
                "intervention_name": "antiandrogen", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Androgen suppression + EBRT + Brachytherapy", 
                "description": "4500 cGy total dose given days 1-5 for 5 weeks following initiation of androgen suppression (25 fractions)", 
                "intervention_name": "radiation therapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Androgen suppression + EBRT + Brachytherapy", 
                "description": "Iodine 125 0.3 to 0.5 U per seed OR palladium 103 1.04 to 1.4 U per seed as implant; prescribed dose of I-125 100 Gy (TG-43) and Pd-103 90 Gy", 
                "intervention_name": "Brachytherapy boost", 
                "intervention_type": "Radiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Androgen Antagonists", 
                "Androgens"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "adenocarcinoma of the prostate", 
            "stage I prostate cancer", 
            "stage II prostate cancer", 
            "stage III prostate cancer"
        ], 
        "lastchanged_date": "September 25, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/CALGB-99809"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Lewes", 
                        "country": "United States", 
                        "state": "Delaware", 
                        "zip": "19958"
                    }, 
                    "name": "Beebe Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newark", 
                        "country": "United States", 
                        "state": "Delaware", 
                        "zip": "19718"
                    }, 
                    "name": "CCOP - Christiana Care Health Services"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wilmington", 
                        "country": "United States", 
                        "state": "Delaware", 
                        "zip": "19805"
                    }, 
                    "name": "St. Francis Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32803"
                    }, 
                    "name": "Florida Hospital Cancer Institute at Florida Hospital Orlando"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Elkton MD", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21921"
                    }, 
                    "name": "Union Hospital Cancer Center at Union Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Brigham and Women's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fall River", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02721"
                    }, 
                    "name": "Hudner Oncology Center at Saint Anne's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Worcester", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01655"
                    }, 
                    "name": "UMASS Memorial Cancer Center - University Campus"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbia", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "65203"
                    }, 
                    "name": "Ellis Fischel Cancer Center at University of Missouri - Columbia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64131"
                    }, 
                    "name": "CCOP - Kansas City"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63141"
                    }, 
                    "name": "Arch Medical Services, Incoroporated at Center for Cancer Care Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63131"
                    }, 
                    "name": "Missouri Baptist Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reno", 
                        "country": "United States", 
                        "state": "Nevada", 
                        "zip": "89502"
                    }, 
                    "name": "Washoe Cancer Services at Washoe Medical Center - Reno"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Camden", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08103"
                    }, 
                    "name": "Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14263"
                    }, 
                    "name": "Roswell Park Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Syracuse", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "13057"
                    }, 
                    "name": "CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Syracuse", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "13215"
                    }, 
                    "name": "Community General Hospital of Greater Syracuse"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Syracuse", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "13210"
                    }, 
                    "name": "SUNY Upstate Medical University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Syracuse", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "13210"
                    }, 
                    "name": "Veterans Affairs Medical Center - Syracuse"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28233"
                    }, 
                    "name": "Presbyterian Cancer Center at Presbyterian Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Goldsboro", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27534"
                    }, 
                    "name": "Wayne Memorial Hospital, Incorporated"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wilmington", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28401"
                    }, 
                    "name": "Zimmer Cancer Center at New Hanover Regional Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winston-Salem", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27157"
                    }, 
                    "name": "Comprehensive Cancer Center at Wake Forest University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Danville", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "24541"
                    }, 
                    "name": "Danville Regional Medical Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Trial of Androgen Suppression for 6 Months Combined With External Beam Radiotherapy (EBRT) With Brachytherapy (BT) Boost for Intermediate Risk Prostate Cancer", 
        "overall_official": {
            "affiliation": "Dana-Farber/Brigham and Women's Cancer Center", 
            "last_name": "Mark Hurwitz, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2007", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "q 3 mon for 2 yrs post tx initiation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00006359"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": [
            {
                "citation": "Hurwitz MD, Halabi S, Archer L, et al.: Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809. [Abstract] 2010 Genitourinary Cancers Symposium, March 5-7, 2010, San Francisco, California. A-192, 2010."
            }, 
            {
                "PMID": "18407435", 
                "citation": "Hurwitz MD, Halabi S, Ou SS, McGinnis LS, Keuttel MR, Dibiase SJ, Small EJ. Combination External Beam Radiation and Brachytherapy Boost with Androgen Suppression for Treatment of Intermediate-Risk Prostate Cancer: An Initial Report of Calgb 99809. Int J Radiat Oncol Biol Phys. 2008 Apr 11; [Epub ahead of print]"
            }, 
            {
                "citation": "Hurwitz MD, Halabi S, Ou SS, et al.: Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate risk prostate cancer: an initial report of CALGB 99-809. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-2230, S337-8, 2006."
            }
        ], 
        "secondary_outcome": [
            {
                "measure": "Time to PSA failure", 
                "safety_issue": "No", 
                "time_frame": "6 years"
            }, 
            {
                "description": "Progression free and overall survival will be assessed", 
                "measure": "Survival", 
                "safety_issue": "No", 
                "time_frame": "6 years"
            }
        ], 
        "source": "Alliance for Clinical Trials in Oncology", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Cancer and Leukemia Group B", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2000", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }, 
    "geocoordinates": {
        "Arch Medical Services, Incoroporated at Center for Cancer Care Research": "38.627 -90.199", 
        "Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University": "39.961 -82.999", 
        "Beebe Medical Center": "38.775 -75.139", 
        "Brigham and Women's Hospital": "42.358 -71.06", 
        "CCOP - Christiana Care Health Services": "39.684 -75.75", 
        "CCOP - Kansas City": "39.1 -94.579", 
        "CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.": "43.048 -76.147", 
        "Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees": "39.926 -75.12", 
        "Community General Hospital of Greater Syracuse": "43.048 -76.147", 
        "Comprehensive Cancer Center at Wake Forest University": "36.1 -80.244", 
        "Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute": "42.358 -71.06", 
        "Danville Regional Medical Center": "36.586 -79.395", 
        "Ellis Fischel Cancer Center at University of Missouri - Columbia": "38.952 -92.334", 
        "Florida Hospital Cancer Institute at Florida Hospital Orlando": "28.538 -81.379", 
        "Hudner Oncology Center at Saint Anne's Hospital": "41.701 -71.155", 
        "Missouri Baptist Cancer Center": "38.627 -90.199", 
        "Presbyterian Cancer Center at Presbyterian Hospital": "35.227 -80.843", 
        "Roswell Park Cancer Institute": "42.886 -78.878", 
        "SUNY Upstate Medical University Hospital": "43.048 -76.147", 
        "St. Francis Hospital": "39.746 -75.547", 
        "UMASS Memorial Cancer Center - University Campus": "42.263 -71.802", 
        "Union Hospital Cancer Center at Union Hospital": "39.607 -75.833", 
        "Veterans Affairs Medical Center - Syracuse": "43.048 -76.147", 
        "Washoe Cancer Services at Washoe Medical Center - Reno": "39.53 -119.814", 
        "Wayne Memorial Hospital, Incorporated": "35.385 -77.993", 
        "Zimmer Cancer Center at New Hanover Regional Medical Center": "34.226 -77.945"
    }
}